Announcements Trials
Browse Landscape

Phase

Phase 2 18Phase NA 7Phase 1/2 5Phase 3 3Phase 2/3 3Phase 1 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Nasopharyngeal Carcinoma 6Triple Negative Breast Neoplasms 4Esophageal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Carcinoma, Hepatocellular 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Neoplasm Metastasis 2Nasopharyngeal Neoplasms 2Lung Neoplasms 2Thoracic Neoplasms 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Radiation Pneumonitis 1Pancreatic Neoplasms 1PD-L1 Positive Non-small Cell Lung Cancer 1Non-squamous Non-small-cell Lung Cancer 1Neoplasms by Site 1Lung Diseases 1Locally Advanced Gastric Cancer 1Esophageal Malignant Neoplasm, Local Recurrence 1Carcinoma, Bronchogenic 1Bronchial Neoplasms 1Breast Neoplasms 1Advanced NSCLC 1Advanced Esophageal Cancer 1

Interventions

Sorafenib 42lenvatinib 21Fluorouracil 16atezolizumab 15Oxaliplatin 14Bevacizumab 13Doxorubicin 12Radiosurgery 11Leucovorin 11Radiofrequency Ablation 10Ethiodized Oil 10pembrolizumab 7Folfox protocol 7sintilimab 6durvalumab 6Radiotherapy 6Nivolumab 6Epirubicin 6Cisplatin 6tremelimumab 5Gemcitabine 5apatinib 4Embolization, Therapeutic 4tislelizumab 3camrelizumab 3cabozantinib 3Tenofovir 3Pharmaceutical Preparations 3Mitomycin 3Magnetic Resonance Spectroscopy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Carcinoma, Hepatocellular × camrelizumab × Clear all
NCT05198609 2026-01-21

Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial

Sun Yat-sen University

Phase 3 Active not recruiting
214 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT04639180 2025-12-30

A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Active not recruiting
687 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT05613478 2024-12-31

Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma

The First Affiliated Hospital with Nanjing Medical University

Phase 3 Recruiting
130 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡